ICOS and neoplasm: However, when comparing baseline with post ipilimumab treated tumors, an increased presence of CD4 T cells that express high levels of inducible T-cell co-stimulator (ICOS) has been correlated repeatedly with improved patient outcomes across multiple tumor types6–9.